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Objectives: Chronic recurrent multifocal osteomyelitis (CRMO), the most severe form 
of chronic nonbacterial osteomyelitis (CNO), is an autoinflammatory bone disorder. In 
the absence of diagnostic criteria or biomarkers, CNO/CRMO remains a diagnosis of 
exclusion. The aim of this study was to identify biomarkers for diagnosing multifocal 
disease (CRMO).
study design: Sera from 71 pediatric CRMO patients, 11 patients with osteoarticular 
infections, 62 patients with juvenile idiopathic arthritis (JIA), 7 patients with para-infec-
tious or reactive arthritis, and 43 patients with acute leukemia or lymphoma, as well as 
59 healthy individuals were collected. Multiplex analysis of 18 inflammation- and/or bone 
remodeling-associated serum proteins was performed. Statistical analysis included uni-
variate ANOVA, discriminant analysis, univariate receiver operating characteristic (ROC) 
analysis, and logistic regression analyses.
results: For 14 of 18 blood serum proteins, significant differences were determined 
between CRMO patients, at least one alternative diagnosis, or healthy controls. Multi-
component discriminant analysis delivered five biomarkers (IL-6, CCL11/eotaxin, CCL5/
RANTES, collagen Iα, sIL-2R) for the diagnosis of CRMO. ROC analysis allowed further 
reduction to a core set of 2 biomarkers (CCL11/eotaxin, IL-6) that are sufficient to discern 
between CRMO, healthy controls, and alternative diagnoses.
Abbreviations: CCL, chemokine (C-C motif) ligand; CNO, chronic nonbacterial osteomyelitis; CRMO, chronic recurrent 
multifocal osteomyelitis; CrP, C-reactive protein; Eotaxin, C-C motif chemokine 11, also known as eosinophil chemotactic 
protein and eotaxin-1; IL, interleukin; IL-1RA, IL-1 receptor antagonist; JIA, juvenile idiopathic arthritis; MIP, macrophage 
inflammatory protein; RANKL, receptor activator of nuclear factor kappa-B ligand; RANTES, regulated on activation, normal 
T cell expressed and secreted protein, also known as chemokine (C-C motif) ligand 5 (CCL5); sIL-2R, soluble IL-2 receptor; 
sJIA, systemic juvenile idiopathic arthritis; SPARC, secreted protein acidic and rich in cysteine; TNF-α, tumor necrosis factor 
α; TRANCE, TNF-related activation-induced cytokine.
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conclusion: Serum biomarkers CCL11/eotaxin and IL-6 differentiate between patients 
with CRMO, healthy controls, and alternative diagnoses (leukemia and lymphoma, 
osteoarticular infections, para-infectious arthritis, and JIA). Easily accessible biomarkers 
may aid in diagnosing CRMO. Further studies testing biomarkers in larger unrelated 
cohorts are warranted.
Keywords: chronic nonbacterial osteomyelitis, chronic recurrent multifocal osteomyelitis, inflammation, 
biomarker, autoinflammation, diagnosis
KeY Messages
•	 Serum CCL11/eotaxin and IL-6 allow differentiation between 
patients with chronic recurrent multifocal osteomyelitis 
(CRMO), healthy controls, and alternative diagnoses.
•	 Easily accessible biomarkers can aid in diagnosing CRMO.
•	 Further studies are needed to validate biomarkers in larger 
unrelated cohorts.
inTrODUcTiOn
Chronic nonbacterial osteomyelitis (CNO) is an autoinflam-
matory bone disorder. Some patients exhibit monofocal and 
timely limited bone inflammation, while others develop 
chronically active or recurrent bone inflammation at multiple 
sites. This most severe presentation of CNO is referred to as 
CRMO (1–3). Despite intense efforts and some scientific 
progress over the recent years, the understanding of the patho-
physiology of CNO/CRMO is still rudimentary. We recently 
demonstrated that monocytes from patients with severe and 
multifocal CRMO are characterized by impaired expression 
of the immune-regulatory cytokines interleukin (IL-)10 and 
IL-19, favoring the expression of pro-inflammatory cytokines 
(IL-1β, IL-6, IL-20, TNF-α). Though subsequent activation of 
osteoclasts has been suggested, the exact contribution of altered 
cytokine expression to bone inflammation and bone-loss 
remains somewhat unclear (3–7).
In the absence of widely accepted diagnostic criteria and 
disease biomarkers, CNO/CRMO remains a diagnosis of exclu-
sion (3, 8, 9). Diagnosis may be delayed by unawareness of the 
disorder, variable clinical presentations, and sometimes rather 
mild symptoms. “Classical” inflammatory parameters, such as 
leukocyte counts, erythrocyte sedimentation rate (ESR), and 
C-reactive protein (CrP) are frequently normal or only mildly 
elevated. Furthermore, several autoimmune/inflammatory 
disorders, including oligoarticular juvenile idiopathic arthritis 
(JIA), share symptoms with CRMO. The absence of severe 
symptoms in individual cases, and lacking elevation of routine 
inflammation markers do not correlate with disease outcomes. 
Thus, the establishment of disease biomarkers for the diagnosis 
of CNO/CRMO is urgently needed (1–3, 8, 9).
Recently, we presented a set of serum biomarkers, including 
cytokines and chemokines that allowed discerning between 
CRMO, Crohn’s disease, and healthy individuals (10). However, 
we failed to discriminate between sera from patients with 
CRMO and JIA. Furthermore, other important differential 
diagnoses, including malignancies (acute leukemia, lymphoma) 
or osteoarticular infections, were missing (10). Here, we assessed 
18 serum proteins to establish a set of serum biomarkers that 
allow discerning between healthy individuals, CRMO patients, 
and individuals with important differential diagnoses (JIA, 
osteoarticular infections, reactive arthritis, acute leukemia, and 
lymphoma).
MaTerials anD MeThODs
Patients and controls
Seventy-one pediatric patients with multifocal recurrent 
CNO, referred to as CRMO, 62 patients with JIA, 43 patients 
with either acute leukemia (N = 34) or lymphoma (N = 9), 11 
patients with osteoarticular infections, and 7 individuals with 
reactive or para-infectious arthritis were included in the study. 
In the absence of evaluated diagnostic tools, CNO was defined 
using the clinical score from Jansson et al., additional labora-
tory findings, bone biopsies, and magnetic resonance imaging 
studies (3, 8, 9). All included patients developed multifocal 
CRMO. Serum samples from 20 out of the 71 CRMO patients 
and none of the other patients or controls enrolled in this study 
were also included in a previous analysis (10). Most samples 
were collected at University Children’s Hospital Dresden, 
some CRMO and JIA serum samples were from University 
Children’s Hospital Würzburg (10) (Data Supplement S1 in 
Supplementary Material). Samples were collected at diagnosis 
(from mostly treatment naïve patients, some JIA patients had 
received NSAIDs as needed) and stored at the bio-repository 
of the Institute of Microbiology, Faculty of Medicine Carl 
Gustav Carus, or University Children’s Hospital Würzburg until 
analysis. As normal controls, serum samples from 59 matched 
healthy individuals were collected at University Children’s 
Hospital Würzburg. The Ethics Committees of the University of 
Technology Dresden and the University of Würzburg approved 
collection and use of these samples. Serum samples from patients 
with other diagnoses were collected during routine care and 
stored in the bio-repository for potential additional diagnostic 
tests. Retrospective sample identification, collection and use of 
anonymized samples were approved by the Ethics Committe of 
the University of Technology Dresden. Since ethics approval 
required complete anonymization of all samples, retrospective 
analyses of JIA disease activity or long-term outcomes was 
impossible.
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Measurement of serum inflammatory 
Parameters
Blood samples were collected following standard procedures, 
and subjected to centrifugation. The liquid phase was separated 
from the pellets, transferred to cryo-tubes, and stored at −80°C 
until further use. According to manufacturer’s instructions, 
serum samples were diluted with LUMINEX buffer reagent 
(R&D Technologies) (1:1), and cytokines (IL-6, IL-10, IL-12p70, 
IL-18, IL-19, TNF-α, TRANCE/RANKL), chemokines (CCL2/
MCP-1, CCL4/MIP-1β, CCL5/RANTES, CCL11/Eotaxin), the 
inflammatory protein S100A8, soluble cytokine receptors and 
antagonists (IL-1RA, sIL-2R), and bone metabolism markers 
(collagen Iα, osteopontin, osteoprotegerin, SPARC/osteonectin) 
were measured using a custom 18-plex (multiplex) assay (R&D 
Technologies) on the Luminex® 200™ platform. Following this 
approach, all measured concentrations were within the detection 
range of the assay.
statistical analysis
Serum protein levels that were below the detection range of 
our multiplex assay were set to “0.” Because of absent normal 
distribution of collected data, results are presented as dot blots, 
indicating mean values and SDs (inflammatory markers at time 
of diagnosis). For data analyses, JIA patients were subdivided in 
two groups (ANA positive oligoarticular JIA, and “other” JIA), 
since no statistical differences were determined between the fol-
lowing subgroups: polyarticular JIA (RF positive or negative), 
psoriatic arthritis, and enthesitis associated HLA-B27 positive 
JIA (ANOVA tests with post  hoc Bonferroni adjustment; data 
not shown). Values from patients with para-infectious and 
reactive arthritis (“reactive”), or osteoarticular infections and 
Lyme arthritis (“infections”) were combined due to the lack of 
statistical differences between the individual diseases (data not 
shown).
For the comparison of serum inflammatory markers between 
controls and patients with CRMO, JIA, lymphoma or leukemia, 
osteoarticular infections, and reactive or para-infectious arthritis, 
data were analyzed using non-parametric univariate ANOVA 
tests (variance analysis) applying Bonferroni correction and 
pairwise comparison. Discriminant analysis was used to test 
biomarkers for their potential to discriminate between groups. 
Univariate receiver operating characteristic (ROC) analysis and 
logistic regression analysis were used to discriminate between 
groups based on single parameters. Statistical analyses were 
performed using SPSS software for windows (IBM, Chicago, IL, 
USA), version 23. Correlation analyses were performed using 
GraphPadPrism version 6.00 for Windows (GraphPad Software, 
La Jolla, CA, USA), and Pearson’s correlation coefficients were 
calculated.
resUlTs
serum levels of inflammation Markers
Based on data from a previous study (10), cytokines (IL-6, 
IL-12p70), chemokines (CCL2/MCP-1, CCL4/MIP-1β, CCL5/
RANTES, CCL11/Eotaxin), and regulatory molecules (IL-1RA, 
sIL-2R) with differential serum concentrations in patients with 
CNO as compared to Crohn’s disease or JIA, and healthy indi-
viduals were included. Based on reports indicating that CNO is 
an autoinflammatory bone disorder with increased expression 
of monocyte-derived innate mediators of inflammation, the 
inflammatory protein S100A8, and bone metabolism markers 
(collagen Iα, osteopontin, osteoprotegerin, SPARC/osteonectin) 
were included (5, 7, 11, 12).
For the comparison of serum inflammatory markers between 
healthy controls, patients with CRMO, and disease controls 
(JIA, acute leukemia or lymphoma, osteoarticular infections, 
and reactive or para-infectious arthritis), data were analyzed 
using non-parametric univariate ANOVA tests (variance 
analysis) applying post hoc Bonferroni correction and pairwise 
comparison (Data Supplement S2 in Supplementary Material; 
Figure S1 in Supplementary Material; Figure  1). The serum 
concentration of the chemokines and cytokines IL-12p70, 
IL-19, CCL2/MCP-1, and osteopontin were either below the 
detection range in all groups (IL-19) or did not show significant 
differences between normal controls and any of the disease 
groups and therefore are not included in figures (IL-12p70, 
osteopontin).
Patients with CRMO exhibited significantly increased serum 
levels of the cytokine IL-6 when compared to all other disease 
groups and healthy controls. All disease groups (including 
CNO/CRMO) were characterized by significantly reduced 
serum levels of CCL11/eotaxin as compared to healthy indi-
viduals. In the CRMO group, serum protein levels were above 
the levels in sera from healthy controls for the following param-
eters: CCL4/MIP-1β, CCL5/RANTES, IL-6, S100A8, sIL-2R, 
IL-1RA, IL-10, and collagen Iα (Figure S1 in Supplementary 
Material). When compared to sera from patients with ANA 
positive oligoarticular JIA, samples from CRMO patients had 
reduced levels of TRANCE/RANKL and CCL4/MIP-1β, but 
increased levels of IL-6. Serum samples from CRMO patients 
contained higher concentrations of CCL4/MIP-1β, CCL5/
RANTES, CCL11/eotaxin, S100A8, and lower concentrations 
of IL-18, sIL-2R, and osteoprotegerin when compared to 
samples from patients with acute leukemia. When compared 
to sera from patients with lymphoma, samples from CRMO 
patients exhibited reduced levels of sIL-2R and increased levels 
of collagen Iα (Figure 1; Figure S1 and Data Supplement S2 in 
Supplementary Material).
Discrimination between groups
To test whether the included serum parameters allow for 
discernment among healthy individuals, patients with alterna-
tive inflammatory conditions (JIA), infections (osteoarticular 
infections and Lyme disease), para-infectious disorders (reac-
tive arthritis and para-infectious arthritis), malignancies (acute 
leukemia and lymphoma), and CRMO, discriminant analysis 
were performed (Figure 2). Standardized canonical discrimi-
nant coefficients were calculated and structure matrices were 
generated (Data Supplement S3 in Supplementary Material). 
Two functions were computer predicted: function 1 cor-
related with CCL11/eotaxin, collagen Iα, and IL-10; function 
2 correlated with IL-6, sIL-2R, CCL5/RANKL, and S100A8 
FigUre 1 | Serum inflammation markers in chronic recurrent multifocal osteomyelitis (CRMO) and alternative diagnoses. Serum inflammation markers were 
determined in samples from 71 CRMO patients, 11 patients with osteoarticular infections, 62 patients with various forms of juvenile idiopathic arthritis (JIA), 7 
patients with para-infectious or reactive arthritis, and 43 patients with acute leukemia or lymphoma, as well as 59 healthy individuals using a custom multiplex assay 
(R&D Systems) on the Luminex® 200™ platform. For the displayed inflammation markers, serum levels were detectable and significantly different for at least two of 
the groups. p values from univariate ANOVA tests applying Bonferroni correction and pairwise comparison are given. Adjusted p values of <0.05 were considered 
statistically significant.
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(Figure 2). Through discriminant analyses, differentiation bet-
ween healthy individuals, CRMO patients, and patients with 
alternative diagnoses was possible. However, serum parameters 
did not discern between the individual differential diagnoses 
(JIA, lymphoma, leukemia, infectious, and reactive arthritis) 
(not shown).
To assess which parameters may be applicable as biomark-
ers for the diagnosis of CRMO and the exclusion of important 
alternative diagnoses, univariate ROC analysis was performed 
(Figure S2 in Supplementary Material). ROC analysis delivered 
CCL11/eotaxin as a promising candidate in the search for 
biomarkers differentiating between all included conditions and 
healthy controls (Figure S2A in Supplementary Material), and 
IL-6 as a potential biomarker discriminating between CRMO 
and all others (healthy controls and included inflammatory 
conditions) (Figure S2B in Supplementary Material). In addition 
to CCL11/eotaxin, ROC analysis suggested CCL5/RANTES, 
collagen Iα, and sIL-2Rα as potential diagnostic biomarkers. 
Thus, in a next step, histograms were generated, displaying the 
distribution of values in all groups (Figure  3). Only CCL11/
eotaxin and IL-6 exhibited minimal overlap between groups 
(CCL11/eotaxin: CRMO and disease controls vs. healthy 
controls; IL-6: CRMO vs. disease and healthy controls), and cut-
off values were identified. Starting with predicted cutoff points 
from univariate ROC analyses (CCL11/eotaxin: 102.44 pg/mL; 
IL-6: 14.976  pg/mL), we manually tested for the number of 
correct or incorrect predictions applying both parameters 
together. We predicted that CCL11/eotaxin levels >110 pg/mL 
may discriminate between healthy controls and inflammatory 
disorders, while IL-6 levels >17  pg/mL may discern between 
CRMO patients and all included controls (healthy and alterna-
tive diagnoses). Following this approach, prediction accuracy 
based on the selected values was tested (Data Supplement S4 in 
Supplementary Material). Two possible alternative approaches 
were compared: (i) discrimination between CRMO patients and 
individuals with alternative diagnoses starting with stratification 
based on IL-6 levels, followed by CCL11/eotaxin levels (Data 
Supplement S4A in Supplementary Material). Sensitivity of the 
approach was 93% and specificity was 97% (positive predictive 
value/PPV: 97%; negative predictive value/NPV: 95%). CRMO 
patients were discernable from healthy individuals with a sensi-
tivity of 100% and a specificity of 98% (PPV: 98%; NPV: 100%). 
Lastly, CRMO patients were identified from all other samples 
(healthy plus disease controls) with a sensitivity of 94% and a 
FigUre 2 | Diagnostic biomarkers for chronic recurrent multifocal 
osteomyelitis (CRMO). To test the applicability of serum proteins for 
discriminating between healthy individuals, patients with CRMO or alternative 
diagnoses, a discriminant analysis between the disease groups and healthy 
controls was performed. Standardized canonical discriminant coefficients 
were calculated and structure matrices were generated. Two functions were 
computer predicted. As indicated, function 1 correlates with CCL11/eotaxin, 
collagen Iα, and IL-10; function 2 correlates with IL-6, sIL-2R, CCL5/RANKL, 
and S100A8. Discrimination analyses with 2 functions, allow for differentiation 
among CRMO patients, healthy controls, and patients with alternative 
diagnoses.
FigUre 3 | Cutoff value prediction. Histograms were generated, displaying the distribution of values from Figure 2 in all groups. Black lines reflect distribution 
curves (ideal curve that mean values and corresponding SDs would deliver). Only for CCL11/eotaxin and IL-6 minimal overlap between groups was determined,  
and cutoff values were identified (red lines, numbers indicate cutoff values in pg/mL).
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specificity of 97% (PPV: 93%, NPV: 97%). (ii) Stratification based 
on CCL11/eotaxin levels, followed by IL-6 (Data Supplement 
S4B in Supplementary Material), delivered discrimination with 
a sensitivity of 100% and a specificity of 87% (PPV: 95%; NPV: 
96%). CRMO patients were discernable from healthy individuals 
with a sensitivity of 93% and a specificity of 97% (PPV: 89%, 
NPV: 100%). Lastly, CRMO patients were identified from all 
other samples (healthy plus disease controls) with a sensitivity 
of 92% and a specificity of 94% (PPV: 84%, NPV: 97%).
To validate data, we performed canonical discriminant 
analysis, exclusively including the two remaining characteristics 
(Figure  4A; Data Supplement S5 in Supplementary Material). 
Indeed, serum samples from all three groups were discernable 
based on CCL11/eotaxin (function 1), and IL-6 (function 2). 
This was confirmed by scatter plot analysis (Figure  4B) show-
ing clustering on measured values, based on disease group. Dot 
plot diagrams and subsequent ANOVA analysis with Bonferroni 
correction assured minimal or no overlap in the distribution of 
measured values between groups (Figure 4C; Data Supplement 
S6 in Supplementary Material).
correlation analyses
To exclude potential correlation between patient characteristic 
and CCL11/eotaxin levels, correlation analysis was performed. 
Indeed, CCL11/eotaxin levels did not correlate with patient age 
(Figure S3A in Supplementary Material). Since patients with 
FigUre 4 | Validation of CCL11/eotaxin and IL-6 as serum biomarkers. (a) To test the applicability of serum IL-6 and CCL11/eotaxin for discriminating between 
healthy individuals, patients with chronic recurrent multifocal osteomyelitis (CRMO) or alternative diagnoses, a subsequent discriminant analysis between the disease 
groups and healthy controls was performed. (B) Serum levels of IL-6 and CCL11/eotaxin were plotted to test clustering within groups. Based on predictions from 
Figure 3, cutoff values were included as red lines. (c) Dot plots indicate ranges of IL-6 (left) and CCL11/eotaxin (right) values in sera from patient with alternative 
diagnoses, CRMO patients, or healthy controls.
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the included alternative diagnoses exhibited reduced CCL11/
eotaxin serum levels when compared to controls, correlation 
between CrP and CCL11/eotaxin serum levels was tested. 
Of note, serum levels of CCL11/eotaxin correlated with CrP 
levels in patients with the included diagnoses (Figure S3B in 
Supplementary Material).
DiscUssiOn
The autoinflammatory disorder CNO is a diagnosis of exclu-
sion. Clinical overlaps with other inflammatory conditions, 
infections, and malignancies (acute leukemia and lymphoma) 
further complicate the situation (8, 9). Here, we measured 18 
and identified 14 markers in sera from CRMO patients that 
were different between CRMO and at least one of the alterna-
tive diagnoses and/or healthy controls. In agreement with 
previous observations (10), elevated proteins in the serum of 
CRMO patients included cytokines (IL-6, RANKL/TRANCE), 
chemokines (CCL4/MIP-1b), and the soluble IL-2 receptor 
(sIL-2R).
cytokines
The anti-inflammatory molecule IL-1RA, the pro-inflammatory 
effector cytokines IL-6 and TNF-α, and the pro-inflammatory 
calcium binding molecule S100A8 (which is actually not consid-
ered a cytokine) were significantly elevated in sera from CRMO 
and/or other differential diagnoses when compared to healthy 
controls. We previously reported increased inflammasome acti-
vation and IL-1β expression in monocytes from CRMO patients. 
Activation of inflammatory caspase-1 is a central function of 
the NLRP3 inflammasome. IL-1β is a very unstable cytokine, 
which makes it virtually impossible to measure in routine serum 
samples. Here, IL-1RA levels were increased in sera from CRMO 
patients when compared to healthy controls, indirectly indicat-
ing increased inflammasome activation and IL-1β release. The 
post-translational regulator IL-1RA, however, directly reflects 
IL-1β release and may therefore be used as an indirect marker 
for IL-1β secretion (13). In a previous study (10), serum IL-1RA 
was not different between CRMO patients, JIA patients and 
healthy individuals. Differences between here presented data 
and previous observations may be explained with varying 
sensitivity between detection systems, since IL-1RA is usually 
considered a quite robust marker of inflammasome activation. 
In addition to IL-1β cleavage and activation, caspase-1 is also 
responsible for the activation of the pro-inflammatory cytokine 
IL-18 (14, 15). IL-18 is expressed by monocytes, lymphocytes, 
eosinophils, mast cells, and others. Main functions of IL-18 are 
monocyte activation, and the induction of pro-inflammatory 
cytokine expression (15, 16). Indeed, serum levels of IL-18 were 
increased in CRMO patients when compared to healthy controls. 
This, however, (likely due to large inter-individual variation) did 
not reach statistical significance.
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The pro-inflammatory molecule S100A8 is secreted by 
monocytes and neutrophils, likely reflecting inflammasome 
activation and the induction of NF-κB signaling pathways (17). 
Indeed, S100A8 serum levels were increased in sera from CRMO 
patients when compared to healthy controls and individuals with 
leukemia. However, differences were small and inter-individual 
variation was relatively large.
Pro-inflammatory IL-6 is mainly produced by monocytes, 
fibroblasts, B and T cells, and plays a role in B and T cell activa-
tion and proliferation (18, 19). Inflammasome activation and 
resulting NF-κB signaling also plays a role in the regulation of 
IL-6 (16, 20). B and T cell-promoting effects of both cytokines 
IL-6 and IL-1β, may furthermore play a role during inflam-
matory responses in CRMO, since neutrophils and monocytes 
(which produce IL-6 and IL-1β) are the predominant cells 
in the acute phase of bone inflammation, while later stages 
are characterized by lymphocyte and plasma cell infiltration 
(2). Provided significant differences in serum protein levels, 
particularly IL-6 may be used to differentiate between CNO/
CRMO, alternative included disorders and healthy controls. 
However, serum samples in (the few) patients with osteoarticu-
lar infections included in this study may have been collected 
in the post-acute phase. None of the included individuals were 
reported with high fever, highly inflamed joints, or massive CrP 
elevation. Thus, IL-6 may not be a good marker to differenti-
ate between acute, febrile and highly inflammatory bacterial 
osteomyelitis and CRMO. This hypothesis is supported by 
the observation that IL-6 serum levels also normalize (quite 
rapidly) in CRMO patients in response to the introduction of 
treatment with NSAIDs (10).
The pro-inflammatory cytokine TNF-α is primarily produced 
by innate immune cells, osteoblasts, and smooth muscle cells. 
Key functions are monocyte activation, induction of osteoclast 
generation and activation, and the induction of cytokine 
expression (16, 20). In agreement with previous reports, serum 
TNF-α levels were increased in samples from CRMO patients 
(5, 7, 12). However, no differences could be detected between 
samples from CRMO patients and other included disorders. 
The osteoclast-promoting TNF-superfamily cytokine RANKL/
TRANCE, however, showed a trend toward increased serum 
levels in CRMO/CNO as compared to healthy controls, which 
failed to reach statistical significance (16). RANKL/TRANCE 
serum levels in ANA positive oligoarticular JIA patients, 
however, were elevated when compared to CNO/CRMO, other 
differential diagnoses (acute leukemia, lymphoma), and healthy 
controls.
Some of our observations at first appear contradictory 
to previous studies. The immune-regulatory cytokine IL-10 
fails to be expressed in monocytes from patients with CRMO 
(5, 7, 11, 12). In a previous serum biomarker study, we did not 
detect IL-10 in any of the disease or control groups, including 
CRMO (10). Here, we detected serum IL-10 in sera from all 
groups, including CRMO. This may be most likely due to higher 
sensitivity of the assay used in the present study as compared to 
previously applied assays (10). Indeed, IL-10 levels were slightly 
(but significantly) higher in CRMO patients when compared 
to healthy controls (but not other alternative diagnoses). This 
observation is not entirely surprising, since patients with other 
inflammatory diseases that are generally characterized by failure 
to express IL-10 from one or more cellular compartments may 
exhibit increased IL-10 serum levels when compared to healthy 
controls (e.g., oligoarticular JIA or systemic JIA) (21–26). Since 
CRMO is an inflammatory disorder and provided the fact that 
cells other than monocytes (e.g., lymphocytes, neutrophils, 
dendritic cells, eosinophils, etc., but also epithelia, stroma cells, 
etc.) express IL-10, serum IL-10 does not necessarily reflect gene 
expression from monocytes (27, 28). Furthermore, provided the 
large inter-individual variation in serum IL-10 levels together 
with the relatively small differences between groups, IL-10 was 
excluded from statistical analyses after the initial discriminant 
analysis.
In a previous study, IL-12 serum levels were different bet-
ween patients with CNO vs. Crohn’s disease and JIA vs. healthy 
controls. Though statistically significant, differences were not 
very pronounced and showed overlap between groups (10). 
In contrast to these results, we failed to detect significant dif-
ferences in serum IL-12p70 levels here. This may (as already 
briefly discussed for IL-10) likely be caused by the use of detec-
tion assays from different manufacturers in the two studies. 
Unfortunately, the use of different buffer systems and (prob-
ably even more importantly) different monoclonal detection 
antibodies significantly limit data comparability between many 
LUMINEX-based studies.
chemokines
In agreement with previous reports, two mostly monocyte-
derived chemokines were elevated in the serum of CRMO 
patients as compared to healthy controls (CCL5/RANTES, CCL4/
MIP-1β) (29). Also, monocytes from aseptic osteomyelitis-prone 
Pstpip2-deficient cmo and lupo mice exhibit elevated serum levels 
of CCL4/MIP-1β and IL-6 (30, 31).
Of note, in agreement with previous observations of our 
group and others, the eosinophil attracting chemokine CCL11/
eotaxin was reduced in sera from patients with alternative diag-
noses included in this study when compared to healthy controls 
(10, 32, 33). While CCL11/eotaxin levels vary between reports 
from different groups, they were reported reduced in patients 
with rheumatoid factor negative rheumatoid arthritis (32), and 
JIA patients with severe disease and radiographic progression 
(33). However, CCL11/eotaxin levels were reported increased 
in other inflammatory conditions including autoimmune 
disease (e.g., Sjögren’s syndrome) and infection (pulmonary 
tuberculosis) (34, 35). Regardless of variable results measuring 
CCL11/eotaxin levels in different forms of rheumatic disease, 
one feature reliably persists: JIA patients with high inflamma-
tory activity and/or tendencies toward joint destruction, exhibit 
reduced levels of CCL11/eotaxin (33, 36). The question of 
whether variable pathomechanisms are responsible for incon-
sistent CCL11/eotaxin serum levels remains speculation and is 
beyond the scope of this report. Detection bias between samples 
from controls (from Würzburg) and patients (from Würzburg 
or Dresden) can be excluded, since samples from CRMO and 
JIA patients were collected at both institutions, and followed 
the same patterns with CCL11/eotaxin levels in the same range. 
FigUre 5 | Proposed algorithm aiding the diagnosis of chronic recurrent multifocal osteomyelitis (CRMO). Based on observations in the presented serum protein 
analysis, CCL11/eotaxin may aid in the differentiation between healthy individuals and patients with CRMO or alternative diagnoses. In individuals with serum 
CCL11/eotaxin levels below 110 pg/mL (patients with CRMO or alternative diagnoses), IL-6 serum levels may help to discriminate between CRMO patients and 
individuals with here included alternative diagnoses.
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Furthermore, trends were highly reproducible in two inde-
pendent studies, and with assays from two manufacturers (10). 
Possible explanations for reduced CCL11/eotaxin serum levels 
in patients with here included alternative diagnoses and CRMO 
remain hypothetical and include “uptake,” recruitment to sites 
of inflammation, or cell-surface receptor binding of CCL11/
eotaxin (32, 33). This may be supported by correlation between 
serum CrP and CCL11/eotaxin levels observed in the included 
individuals.
Provided significant differences in serum protein levels, 
eotaxin may be used to differentiate between healthy controls 
and all disease groups. Thus, CCL11/eotaxin may prove valuable 
to discriminate between patients with inflammatory conditions 
included here (including CRMO) and healthy individuals.
Markers of Bone Metabolism
Provided potential effects of disturbed cytokine expression on 
the generation and activation of osteoclasts in CRMO, markers 
of bone remodeling were included in this study (12). Indeed, 
collagen Iα levels were increased in sera from CRMO patients 
as compared to healthy controls and patients with lymphoma, 
potentially indicating bone remodeling in CRMO and some other 
inflammatory conditions (37). Statistically significant differences 
in serum levels of osteoprotegerin were detected between patients 
with CRMO and lymphoma, while all other groups showed 
comparable results. A trend toward increased serum levels of 
SPARC/osteonectin in CRMO patients compared to healthy 
controls, likely due to large inter-individual variation, failed to 
reach statistical significance, while ANA positive oligoarticular 
JIA patients exhibited elevated levels when compared to CRMO 
patients.
Soluble IL-2 receptor concentrations can be measured in the 
serum, and correlate with disease activity and T cell activation 
in a number of inflammatory disorders, including CRMO, as 
well as malignancies (10, 38). Serum sIL-2R levels may be help-
ful for discriminating CRMO patients from individuals with 
acute leukemia and/or lymphoma, since both groups exhibited 
significantly higher serum levels (38). However, relevant overlap 
likely limits the applicability as reliable biomarker differentiation 
between these groups.
Based on aforementioned results, discriminant analyses 
allowed discernment between CRMO, alternative diagnoses, and 
healthy individuals. Particularly the pro-inflammatory cytokine 
IL-6, the chemokines CCL11/eotaxin and CCL5/RANTES, the 
bone remodeling marker collagen Iα, and sIL-2R promise poten-
tial as disease biomarkers for CRMO. Indeed, in the investigated 
cohort, restriction of biomarkers to CCL11/eotaxin and IL-6 
still allowed discrimination between CRMO, important alterna-
tive diagnoses, and healthy individuals with a high sensitivity 
(all >92%) and specificity (all >87%). Based on clinical experi-
ence and the relatively low cutoff for IL-6 serum levels (17 pg/mL), 
screening of CCL11/eotaxin serum levels, followed by IL-6 
serum level determination may be more reasonable. Taken 
together, we for the first time report potentially reliable and 
easily accessible parameters that may find their way into routine 
diagnosis and care of patients with CRMO allowing exclusion of 
differential diagnoses (Figure 5). Correlation between age and 
CCL11/eotaxin levels were (largely) excluded as potential bias. 
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Furthermore, in all groups, CCL11/eotaxin correlated with CrP 
levels.
The inclusion of additional differential diagnoses and further 
serum markers, enabling discrimination between differential 
diagnoses, the presented study significantly extends beyond 
the aims and results of previous studies (10). However, at least 
at this stage, proposed serum markers do certainly not replace 
the exclusion of differential diagnoses. Presented results require 
confirmation in larger unrelated cohorts. Prospectively col-
lected bio samples from patients with CNO/CRMO, various 
forms of JIA, and other inflammatory differential diagnoses 
together with detailed information on clinical activity will 
allow further evaluation of the applicability of serum IL-6 as 
discriminator between CRMO and differential diagnoses. 
A limitation of the presented study is the lack of clinical 
information on disease activity in included inflammatory 
conditions. Bio sample collection and precise documentation of 
clinical data during consensus treatment plan and treat to target 
efforts in large cohorts, as currently planned by the Childhood 
Arthritis and Rheumatology Research Alliance (CARRA) and 
the German Society of Pediatric Rheumatology (GKJR) may 
provide necessary patient numbers and clinical data sets to 
tackle this task.
cOnclUsiOn
Two serum biomarkers (CCL11/eotaxin, IL-6) discriminate 
between CRMO, alternative diagnoses (acute leukemia, lym-
phoma, JIA, osteoarticular infections, and reactive or para-
infectious arthritis), and healthy controls. CCL11/eotaxin 
may be useful for discerning between healthy individuals 
and patients with (non-allergic) inflammatory conditions. 
Confirmation in large and unrelated cohorts is required. 
However, results require to be interpreted with caution sec-
ondary to limited sample size, lacking information on disease 
activity in JIA patients, and the current absence of independent 
control cohorts.
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FigUre s1 | Serum inflammation markers in chronic recurrent multifocal 
osteomyelitis (CRMO) and alternative diagnoses. 18 serum inflammation 
markers were determined in samples from 71 CRMO patients, 11 patients  
with osteoarticular infections, 62 patients with various forms of juvenile 
idiopathic arthritis (JIA), 7 patients with para-infectious or reactive arthritis,  
and 43 patients with acute leukemia or lymphoma, as well as 59 healthy 
individuals using a custom multiplex assay (R&D Systems) on the Luminex® 
200™ platform. For the displayed inflammation markers, serum levels were 
detectable and significantly different for at least two of the groups. p values 
from univariate ANOVA tests applying Bonferroni correction and pairwise 
comparison are given. Adjusted p values of <0.05 were considered  
statistically significant.
FigUre s2 | Identification of optimal biomarkers and cutoff prediction. Receiver 
operating characteristic (ROC) analysis delivered CCL11/eotaxin as a promising 
candidate in the search for biomarkers differentiating between all included 
conditions and healthy controls, and IL-6 as a potential biomarker discriminating 
between chronic recurrent multifocal osteomyelitis (CRMO) and all others. 
Furthermore, ROC analysis suggested CCL5/RANTES, collagen Iα, and sIL-2R 
as potential diagnostic biomarkers.
FigUre s3 | Potential correlation between CCL11/eotaxin and other variables. 
(a) CCL11/eotaxin levels do not correlate with age. (B) CCL11/eotaxin correlates 
with C-reactive protein (CrP) levels in chronic recurrent multifocal osteomyelitis 
(CRMO) patients, and disease controls.
DaTa sUPPleMenT s1 | Demographic information on included patients.
DaTa sUPPleMenT s2 | Univariate ANOVA with Bonferroni correction and 
pairwise comparison [chronic recurrent multifocal osteomyelitis (CRMO) vs. 
controls vs. alternative diagnoses].
DaTa sUPPleMenT s3 | Standardized canonical discriminant analysis.
DaTa sUPPleMenT s4 | Sensitivity and specificity of predictive approach.
DaTa sUPPleMenT s5 | Standardized canonical discriminant analysis with 
two core variables.
DaTa sUPPleMenT s6 | Univariate ANOVA with Bonferroni correction and 
pairwise comparison [chronic recurrent multifocal osteomyelitis (CRMO) vs. 
controls vs. pooled alternative diagnoses].
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